New hope for rare lung cancer: targeted drug trial launches
NCT ID NCT07336732
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called andamertinib, alone or with chemotherapy, against standard chemotherapy in people with advanced non-squamous lung cancer that has unusual EGFR mutations. About 40 participants who have not had prior treatment will be enrolled. The goal is to see if the drug is safe and works better than current options.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Andamertinib (a targeted drug) with or without platinum-based chemotherapy
What this could lead to
If successful, this could provide a new treatment option for people with a rare type of lung cancer that has limited targeted therapies.
What could go wrong
This is an early-phase trial with only 40 participants, so results may not apply broadly. The drug may cause side effects or fail to improve outcomes over standard chemotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-Sen University Cancer Center
RECRUITINGGuangzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••